The National Pharmaceutical Council (NPC) has expressed concerns over the Institute for Clinical and Economic Review’s (ICER) adaptations to its value assessment framework regarding single or short-term transformative therapies (SSTs).
ICER is set to incorporate the updates next year.
” … The final scenarios have significant limitations,” NPC states in a blog post. “ICER is limiting potential cost offsets and arbitrarily capping treatment prices at a set amount.”
To read the full blog post, click here.